Dr Reddys unveils Methylphenidate Hydrochloride ER Tablets in US

Written by Ruchika Sharma Published On 2020-09-04T11:39:44+05:30 | Updated On 4 Sept 2020 11:39 AM IST

Dr Reddys unveils Methylphenidate Hydrochloride ER Tablets in US

Concerta is indicated to treat attention deficit hyperactivity disorder(ADHD).

Hyderabad: Dr. Reddys Laboratories Ltd. on Thursday announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, a therapeutic equivalent generic version of Concerta, in various strengths, in the USA market.

The drug was approved by the U.S. Food and Drug Administration (USFDA), a press release from the drug maker said.

Concerta is indicated to treat attention deficit hyperactivity disorder (ADHD).

The Concerta brand and generic market had U.S. sales of approximately USD 1.159 billion MAT for the most recent twelve months ending in June 2020, Dr Reddy''s said quoting market reports.

Dr. Reddys Methylphenidate Hydrochloride Extended- Release Tablets, USP are available in strengths of 18 mg, 27 mg, 36 mg, and 54 mg tablets in bottle count sizes of 100, it said.

dr reddy's labsdr reddy's labs newsmethylphenidate hydrochloride extended release tabletsconcertaattention deficit hyperactivity disorderadhd

Source : PTI

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751